Novartis, Roche, Genentech fined €444.85 million in France in AMD treatment case

The French competition authority, Autorité de la concurrence, has fined the pharmaceutical groups Novartis, Roche and Genentech, a combined €444.85 million for abuse of dominant position to impose the use of the drug Lucentis over its cheaper alternative Avastin in the treatment of age-related macular degeneration (AMD).

You need to register to continue reading this article

Already subscribe to Eyewear intelligence? Sign in here

Register to continue reading

By registering today you will have access to:

  • 3 industry news articles per month

For full access and to receive in-depth news, analysis and more, become a member today

For more content and resources become a member? View our membership packages.